Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EDNRA | P25101 | 20/20 | 0.80 |
| ▸ | EDNRB | P24530 | 13/20 | 0.70 |
| ▸ | ABCC3 | O15438 | 1/20 | 0.63 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.63 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.63 |
| ▸ | PDE4A | P27815 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13324177 | 0.90 | EDNRA (0.86) | EDNRAEDNRBABCC3ABCC4ABCB11 | |
| SCHEMBL4632336 | 0.89 | EDNRA (0.71) | EDNRAEDNRBABCC3ABCC4ABCB11 | |
| SCHEMBL7043215 | 0.89 | EDNRA (0.79) | EDNRAEDNRBABCC3ABCC4ABCB11 | |
| SCHEMBL4661728 | 0.89 | EDNRA (0.81) | EDNRAEDNRBABCC3ABCC4ABCB11 | |
| SCHEMBL802427 | 0.89 | EDNRA (1.00) | EDNRAEDNRBABCC3ABCC4ABCB11 | |
| SCHEMBL4631877 | 0.89 | EDNRA (0.84) | EDNRAEDNRBABCC3ABCC4ABCB11 | |
| SCHEMBL6964790 | 0.89 | EDNRA (0.84) | EDNRAEDNRBABCC3ABCC4ABCB11 | |
| SCHEMBL4632015 | 0.87 | EDNRA (0.81) | EDNRAEDNRBABCC3ABCC4ABCB11 | |
| SCHEMBL4631889 | 0.87 | EDNRA (0.61) | EDNRAEDNRBABCC3ABCC4ABCB11 | |
| SCHEMBL4631364 | 0.87 | EDNRA (0.81) | EDNRAEDNRBABCC3ABCC4ABCB11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1498418-A1 | Sulfonamides for treatment of endothelin-mediated disorders | ENCYSIVE PHARMACEUTICALS INC. (US) | 2005-01-19 | — | — | EP | claimed |
| US-6683103-B2 | SULFONAMIDES CONTAINING OXAZOLE AND SUBSTITUTED THIOPHENE RINGS, USEFUL FOR TREATING HYPERTENSION, CARDIOVASCULAR DISEASE, ASTHMA, PULMONARY HYPERTENSION, INFLAMMATORY DISEASES, VISION DEFECTS, MENSTRUAL DISORDERS, RENAL FAILURE | TEXAS BIOTECHNOLOGY CORPORATION | 2004-01-27 | — | — | US | claimed |
| US-20020091270-A1 | Sulfonamides for treatment of endothelin-mediated disorders | ENCYSIVE PHARMACEUTICALS INC. | 2002-07-11 | — | — | US | claimed |
| CN-1253560-A | Sulfonamides for the treatment of endothelin mediated diseases | TEXA BIOTECHNOLOGY CORP (US) | 2000-05-17 | — | — | CN | claimed |
| EP-1498418-B1 | Sulfonamides for treatment of endothelin-mediated disorders | ENCYSIVE PHARMACEUTICALS INC (US) | 2008-05-21 | — | — | EP | disclosed |
| EP-0980369-B1 | SULFONAMIDES FOR TREATMENT OF ENDOTHELIN-MEDIATED DISORDERS | ENCYSIVE PHARMACEUTICALS INC (US) | 2005-03-30 | — | — | EP | disclosed |
| EP-1498419-A1 | Process for preparing alkali metal salts of hydrophobic sulfonamides | ENCYSIVE PHARMACEUTICALS INC. (US) | 2005-01-19 | — | — | EP | disclosed |
| EP-1498418-A1 | Sulfonamides for treatment of endothelin-mediated disorders | ENCYSIVE PHARMACEUTICALS INC. (US) | 2005-01-19 | — | — | EP | disclosed |
| US-6683103-B2 | SULFONAMIDES CONTAINING OXAZOLE AND SUBSTITUTED THIOPHENE RINGS, USEFUL FOR TREATING HYPERTENSION, CARDIOVASCULAR DISEASE, ASTHMA, PULMONARY HYPERTENSION, INFLAMMATORY DISEASES, VISION DEFECTS, MENSTRUAL DISORDERS, RENAL FAILURE | TEXAS BIOTECHNOLOGY CORPORATION | 2004-01-27 | — | — | US | disclosed |
| US-6432994-B1 | CARDIOVASCULAR DISORDERS, GLAUCOMA; ANTIINFLAMMATORY, WOUND HEALING, HYPOTENSIVE, ANTIASTHMATIC, AND ANTIANAPHYLACTIC AGENTS | TEXAS BIOTECHNOLOGY CORPORATION | 2002-08-13 | — | — | US | disclosed |
| US-20020091270-A1 | Sulfonamides for treatment of endothelin-mediated disorders | ENCYSIVE PHARMACEUTICALS INC. | 2002-07-11 | — | — | US | disclosed |
| WO-2001049289-A1 | PHARMACEUTICAL AND VETERINARY USES OF ENDOTHELIN ANTAGONISTS | TEXAS BIOTECHNOLOGY CORPORATION (US) | 2001-07-12 | — | — | WO | disclosed |
| CN-1253560-A | Sulfonamides for the treatment of endothelin mediated diseases | TEXA BIOTECHNOLOGY CORP (US) | 2000-05-17 | — | — | CN | disclosed |
| EP-0980369-A1 | SULFONAMIDES FOR TREATMENT OF ENDOTHELIN-MEDIATED DISORDERS | TEXAS BIOTECHNOLOGY CORPORATION (US) | 2000-02-23 | — | — | EP | disclosed |
| WO-1998049162-A1 | SULFONAMIDES FOR TREATMENT OF ENDOTHELIN-MEDIATED DISORDERS | TEXAS BIOTECHNOLOGY CORPORATION (US) | 1998-11-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020091270-A1 | Sulfonamides for treatment of endothelin-mediated disorders | EDNRA, ECE1, EDNRB | EDNRA 1/4885EDNRB 3/4885ABCC3 2135/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.